FOLH1 and prostate cancer: <h4>Objective</h4>To conduct a meta-analysis of the efficacy and safety of <sup>225</sup>Ac-PSMA-617 in the treatment of metastatic castration-resistant prostate cancer based on existing clinical evidence.<h4>Methods</h4>Search for retrospective studies about <sup>225</sup>Ac-PSMA-617 in the treatment of metastatic castration-resistant prostate cancer from establishment to July 2021 in PubMed and EMBASE.